Bifogade filer
Kurs
+2,20%
Likviditet
0,03 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-06 | 08:10 | Bokslutskommuniké 2025 |
2025-10-23 | 08:10 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 08:10 | Kvartalsrapport 2025-Q2 |
2025-05-23 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2025-05-22 | - | Årsstämma |
2025-04-16 | - | Kvartalsrapport 2025-Q1 |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-09-23 | - | Extra Bolagsstämma 2024 |
2024-07-05 | - | Kvartalsrapport 2024-Q2 |
2024-05-17 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2024-05-16 | - | Årsstämma |
2024-04-26 | - | Kvartalsrapport 2024-Q1 |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-07-07 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-10 | - | Bokslutskommuniké 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-09-15 | - | Extra Bolagsstämma 2022 |
2022-08-19 | - | Kvartalsrapport 2022-Q2 |
2022-06-03 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2022-06-02 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-08 | - | Bokslutskommuniké 2021 |
2021-10-29 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-28 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2021-05-27 | - | Årsstämma |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-10-30 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-29 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2020-05-28 | - | Årsstämma |
2020-02-26 | - | Extra Bolagsstämma 2020 |
2020-02-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-07 | - | Bokslutskommuniké 2019 |
2019-10-25 | - | Kvartalsrapport 2019-Q3 |
2019-08-27 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-10 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
2018-11-23 | - | Kvartalsrapport 2018-Q3 |
2018-08-23 | - | Kvartalsrapport 2018-Q2 |
2018-06-01 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2018-05-31 | - | Årsstämma |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-02-23 | - | Bokslutskommuniké 2017 |
2017-11-23 | - | Kvartalsrapport 2017-Q3 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-06-02 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2017-06-01 | - | Årsstämma |
2017-05-19 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-09-12 | - | Extra Bolagsstämma 2016 |
2016-08-26 | - | Kvartalsrapport 2016-Q2 |
2016-06-01 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
2016-05-31 | - | Årsstämma |
2016-05-20 | - | Kvartalsrapport 2016-Q1 |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-11-26 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5.
In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May 21, 2025, holders of warrants of series TO5 have had the right to subscribe for shares by virtue of warrants. One (1) warrant of series TO5 entitled the holder to subscribe for one (1) new share in Nanologica at a subscription price set at SEK 3.
A total of 12,586 warrants of series TO5 have been exercised, increasing the number of shares in the company to a total of 88,369,820 shares, and increasing the share capital by SEK 641.886 to a total of SEK 4,506,860.82.
As of June 30, 2025, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 88,369,820.
For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90
About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.
This information is information that Nanologica AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-06-30 11:00 CEST.